Thermal proficiency of magnetized and radiative cross-ternary hybrid nanofluid flow induced by a vertical cylinder

The ternary hybrid nanofluid leads to a significant enhancement in thermal performance applications like heat transfer in automotive engines, solar thermal energy storage, aerospace, and electronic cooling. The present study investigates the thermal characteristics of a ternary hybrid magnetized and radiated cross nanofluid comprising Al2O3, TiO2, and Ag nanoparticles in water subjected to combined convection flow around a vertical cylinder. Furthermore, innovative effects of the magnetic field, absorber surface of the cylinder, non-linear thermal radiations, and effective thermophysical characteristics of ternary nanofluid are taken, and a new model for heat transport is successfully achieved. The governing equations in the form of partial differential equations (PDEs) are obtained through Navier–Stokes and heat equations by applying current assumptions. The system of PDEs is converted into a set of ordinary differential equations (ODEs) via a similarity variable. The built-in code bvp4c in Matlab software further exercises the dimensionless ODE equations numerically. Adding multiple nanoparticles and the magnetic field effect enhances the heat transfer rate in the ternary hybrid cross nanofluid. The Weissenberg number reduces the velocity, the radiation parameter increases heat transport, and the increased volume friction of nanoparticles enhances thermal conductivity and rapid heat transport

HAUD graduation project 2024- Ehkeely Portsaid development plan - Part1

This booklet represents the diligent efforts and scholarly output of our students following their site visits, workshops and comprehensive analysis of Port Said city. The work was conducted during the first semester, Fall 2023/2024 with a primary focus on dissecting the city’s various aspects, identifying gaps, and highlighting challenges. The students, who are in their senior year, have demonstrated commendable dedication and academic rigor in their approach. Their work provides valuable insights into the city’s unique characteristics, strengths, and areas that present opportunities for improvement. We hope that this booklet serves as a testament to their hard work and provides a valuable resource for understanding the multifaceted nature of Port Said city.</p

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)